Weekly issue 2026-W35 ·
Targeting Runx1 slows cyst growth in autosomal dominant polycystic kidney disease
Plain language
Runx1 is a protein that switches many genes on and off. In this laboratory study, Runx1 levels were much higher in kidney cells and tissue lacking a working PKD1 gene. A drug-like compound that blocks Runx1 slowed cyst growth in two kinds of ADPKD mice, one with fast and one with slow disease. Runx1 appeared to help cyst-lining cells multiply, to drive inflammation and to promote scarring in the kidney. It is a possible new treatment target, but the work was done only in cells and mice, not in people.
Clinical note
Preclinical study (FASEB J). Runx1 upregulated in Pkd1-mutant renal epithelial cells and kidneys via a cAMP-dependent mechanism. Selective Runx1 inhibitor Ro5-3335 significantly attenuated cyst progression in rapidly and slowly progressive Pkd1 mouse models. Mechanisms: increased cyst-lining epithelial proliferation (AKT-mTOR, MAPK, STAT3) with suppressed p53-mediated apoptosis; macrophage infiltration and inflammation via NF-κB; interstitial fibrosis via TGF-β/Smad2. Proposes Runx1 as a therapeutic target; mouse and cell data only, no human or safety data.
Question for your next visit
Are any treatments that work on the cAMP pathway, like tolvaptan, suitable for me, and are there trials of newer targets I could ask about?